WO2016163799A3 - 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 - Google Patents

2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 Download PDF

Info

Publication number
WO2016163799A3
WO2016163799A3 PCT/KR2016/003696 KR2016003696W WO2016163799A3 WO 2016163799 A3 WO2016163799 A3 WO 2016163799A3 KR 2016003696 W KR2016003696 W KR 2016003696W WO 2016163799 A3 WO2016163799 A3 WO 2016163799A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
compound
methoxyphenyl
methoxy
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/003696
Other languages
English (en)
French (fr)
Other versions
WO2016163799A2 (ko
Inventor
홍진태
이희범
함영완
김춘식
정현상
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chungbuk National Univiversity CBNU
Original Assignee
Chungbuk National Univiversity CBNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chungbuk National Univiversity CBNU filed Critical Chungbuk National Univiversity CBNU
Priority to US15/564,027 priority Critical patent/US10166203B2/en
Priority to CN201680021186.6A priority patent/CN107530300A/zh
Publication of WO2016163799A2 publication Critical patent/WO2016163799A2/ko
Publication of WO2016163799A3 publication Critical patent/WO2016163799A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 신규 화합물 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀의 항암 용도에 관한 것이다. 본 발명의 화합물은 인 비트로 및 이종이식 동물모델에서 암세포와 종양의 성장을 효과적으로 억제한다. 본 발명의 화합물은 암세포에서 전사인자 STAT3의 DNA 결합 활성을 억제하고, 암세포의 세포사멸(apoptosis)를 유도하며, 세포주기 조절 단백질의 발현을 감소시킴으로써 항암 활성을 나타낸다. 본 발명의 화합물은 강력한 항암제의 활성성분으로 개발될 수 있다.
PCT/KR2016/003696 2015-04-10 2016-04-08 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 Ceased WO2016163799A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/564,027 US10166203B2 (en) 2015-04-10 2016-04-08 Pharmaceutical composition for treating cancer including 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol as active ingredient
CN201680021186.6A CN107530300A (zh) 2015-04-10 2016-04-08 将2‑甲氧基‑4‑(3‑(4‑甲氧基苯基)丙‑1‑烯‑1‑基)苯酚作为有效成分的癌的治疗用药剂学组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0050578 2015-04-10
KR1020150050578A KR101671020B1 (ko) 2015-04-10 2015-04-10 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물

Publications (2)

Publication Number Publication Date
WO2016163799A2 WO2016163799A2 (ko) 2016-10-13
WO2016163799A3 true WO2016163799A3 (ko) 2016-12-01

Family

ID=57071944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003696 Ceased WO2016163799A2 (ko) 2015-04-10 2016-04-08 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물

Country Status (4)

Country Link
US (1) US10166203B2 (ko)
KR (1) KR101671020B1 (ko)
CN (1) CN107530300A (ko)
WO (1) WO2016163799A2 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687751B1 (ko) * 2015-04-09 2016-12-19 주식회사 중헌제약 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3921650A1 (en) 2019-02-08 2021-12-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) * 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN110563563B (zh) * 2019-08-30 2021-06-25 四川大学 一种查耳酮类化合物及其制备方法和用途
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
KR20250051416A (ko) 2023-10-10 2025-04-17 이희범 Mmpp를 유효성분으로 포함하는 제2형 당뇨병 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods
US7598294B2 (en) * 2001-10-03 2009-10-06 Spear Therapeutics Limited 3,4-methylenedioxy-substituted chalcones as therapeutic agents
KR20110087930A (ko) * 2010-01-27 2011-08-03 영남대학교 산학협력단 잔토휴몰 또는 이의 유도체를 함유하는 방사선 항암치료 감수성 증진용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598294B2 (en) * 2001-10-03 2009-10-06 Spear Therapeutics Limited 3,4-methylenedioxy-substituted chalcones as therapeutic agents
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods
KR20110087930A (ko) * 2010-01-27 2011-08-03 영남대학교 산학협력단 잔토휴몰 또는 이의 유도체를 함유하는 방사선 항암치료 감수성 증진용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIYOSHI, H. ET AL.: "2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses Tumor Progression and Metastatic Potential of Breast Cancer Cells by Inducing Ubiquit in Ligase CHIP", SCIENTIFIC REPORTS, vol. 4, no. 7095, 2014, pages 1 - 10, XP055332089 *
PATHAK, V. ET AL.: "Syntheses of 2-methoxyestradiol and Eugenol Template based Diarylpropenes as Non-steroidal Anticancer Agents", RSC ADVANCES, vol. 4, no. 66, 2014, pages 35171 - 35185, XP055332088 *

Also Published As

Publication number Publication date
KR101671020B1 (ko) 2016-11-02
KR20160121685A (ko) 2016-10-20
WO2016163799A2 (ko) 2016-10-13
CN107530300A (zh) 2018-01-02
US10166203B2 (en) 2019-01-01
US20180133168A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
WO2016163799A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물
EP4559902A3 (en) Kdm1a inhibitors for the treatment of disease
HK1199725A1 (en) Heterocyclic compounds and uses thereof
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
HK1207069A1 (en) Heterocyclic compounds and uses thereof
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2014013924A (es) Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
EP3207928A4 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
EP3020405A4 (en) Composition for preventing and treating liver fibrosis or liver cirrhosis,containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells
BR112014011981B8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
BR112017016883A2 (pt) compostos com atividade antitumoral
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
MX2020011500A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16776902

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15564027

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16776902

Country of ref document: EP

Kind code of ref document: A2